AstraZeneca (LON:AZN) Stock Rating Reaffirmed by Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZNGet Rating)‘s stock had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft in a research note issued on Monday, MarketBeat reports. They currently have a £120 ($147.04) price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective points to a potential upside of 13.16% from the stock’s current price.

A number of other research firms have also weighed in on AZN. JPMorgan Chase & Co. set a £120 ($147.04) target price on AstraZeneca in a report on Wednesday, July 13th. Barclays reaffirmed an “overweight” rating and issued a £120 ($147.04) price objective on shares of AstraZeneca in a report on Monday, July 18th. The Goldman Sachs Group set a GBX 6,950 ($85.16) target price on AstraZeneca in a report on Friday, April 29th. Credit Suisse Group set a £110 ($134.79) target price on AstraZeneca in a report on Monday. Finally, UBS Group set a £101 ($123.76) target price on AstraZeneca in a report on Tuesday, June 14th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of £106.13 ($130.04).

AstraZeneca Trading Down 1.6 %

Shares of AstraZeneca stock opened at £106.04 ($129.94) on Monday. AstraZeneca has a 12-month low of GBX 8,029 ($98.38) and a 12-month high of £112.90 ($138.34). The stock has a market cap of £164.31 billion and a P/E ratio of -183.33. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 90.06. The business’s 50 day moving average is £106 and its 200-day moving average is GBX 9,946.92.

About AstraZeneca

(Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Read More

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.